Use of anti-PGL-1 antibodies to monitor therapy regimes in leprosy patients

Brazilian Journal of Medical and Biological Research

Volumn 42, Issue 10, 2009, Pages 968-972

  Zenha, E M R ^a   Ferreira, M A N ^a   Foss, N T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anti PGL 1; Leprosy; MDT 12 months; MDT 24 months; Multidrug therapy

Indexed keywords

CLOZAPINE; DAPSONE; IMMUNOGLOBULIN M; PHENOLIC GLYCOLIPID; PHENOLIC GLYCOLIPID I ANTIBODY; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LEPROSY; MAJOR CLINICAL STUDY; MULTIBACILLARY LEPROSY; TREATMENT DURATION; TREATMENT RESPONSE;

BACTERIA (MICROORGANISMS);

EID: 70649084314     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009001000016     Document Type: Article

References (21)

1. Bach MA, Wallach D, Flageul B, Hoffenbach A, Cottenot F. Antibodies to phenolic glycolipid-1 and to whole Mycobacterium leprae in leprosy patients: evolution during therapy. Int J Lepr Other Mycobact Dis 1986; 54: 256-267. (Pubitemid 16070754)
2. Brett SJ, Draper P, Payne SN, Rees RJ. Serological activity of a characteristic phenolic glycolipid from Mycobacterium leprae in sera from patients with leprosy and tuberculosis. Clin Exp Immunol 1983; 52: 271-279.
3. Foss NT, Callera F, Alberto FL. Anti-PGL1 levels in leprosy patients and their contacts. Braz J Med Biol Res 1993; 26: 43-51. (Pubitemid 23109337)
4. Klatsewr PR. Serology of leprosy. Trop Geogr Med 1994; 46: 115-118.
5. Saad MH, Medeiros MA, Gallo ME, Fonseca LS. Use of the anti-PGL-I antibody ELISA and the Mitsuda reaction in early diagnosis of leprosy. Braz J Med Biol Res 1991; 24: 801-805.
6. Stefani MM, Martelli CM, Morais-Neto OL, Martelli P, Costa MB, de Andrade AL. Assessment of anti-PGL-I as a prognostic marker of leprosy reaction. Int J Lepr Other Mycobact Dis 1998; 66: 356-364. (Pubitemid 128531580)
7. Bakker MI, Hatta M, Kwenang A, Van Mosseveld P, Faber WR, Klatser PR, et al. Risk factors for developing leprosy - a population-based cohort study in Indonesia. Lepr Rev 2006; 77: 48-61.
8. Brasil MTLRF, Oliveira LR, Rímoli NS, Cavallari FS, Gonçalves OS, Lessa ZL, et al. Anti-PGL-1 serology and the risk of leprosy in a highly endemic area in the State of São Paulo, Brazil: four-year follow-up. Rev Bras Epidemiol 2003; 6: 262-271.
9. Cho SN, Yanagihara DL, Hunter SW, Gelber RH, Brennan PJ. Serological specificity of phenolic glycolipid I from Mycobacterium leprae and use in serodiagnosis of leprosy. Infect Immun 1983; 41: 1077-1083.
10. Burgess PJ, Fine PE, Ponnighaus JM, Draper C. Serological tests in leprosy. The sensitivity, specificity and predictive value of ELISA tests based on phenolic glycolipid antigens, and the implications for their use in epidemiological studies. Epidemiol Infect 1988; 101: 159-171. (Pubitemid 18191942)
11. Douglas JT, Steven LM, Fajardo T, Cellona RV, Madarang MG, Abalos RM, et al. The effects of chemotherapy on antibody levels in lepromatous patients. Lepr Rev 1988; 59: 127-135. (Pubitemid 18144830)
12. Barros RPC, Oliveira MLWR. Detection of specific antibodies for the phenolic-1 glycolipid antigen of M. leprae (anti-PGL-1 IgM): applications and limitations. An Bras Dermatol 2000; 75: 745-753.
13. Ministério da Saúde - Brasil. Secretaria de Vigilância em Saúde. Programa Nacional de Eliminação da Hanseníase. Situação da Hanseníase no Brasil. Prevalência e Detecção no ano de 2007. Brasília: Ministério da Saúde, PNEH/DEVEP/SVS/MS; 2008.
14. Ministério da Saúde - Brasil. Portaria No 817 de 26 de julho de 2000 DO 144-E, de 27 de julho de 2000. Brasília: Ministério da Saúde; 2000.
15. Sales AM, Sabroza PC, Nery JA, Duppre NC, Sarno EN. No difference in leprosy treatment outcomes comparing 12- and 24-dose multidrug regimens: a preliminary study. Cad Saude Publica 2007; 23: 815-822.
16. Bonato VLD. Correlação dos anticorpos anti-PGL-I com o índice baciloscópico, a reação de Mitsuda, o tratamento poliquimioterápico e as interleucinas nas diferentes formas da hanseníase. [Master's thesis]: Universidade de São Paulo; 1995.
17. Ridley DS. Therapeutic trials in leprosy using serial biopsies. Lepr Rev 1958; 29: 45-52.
18. McLean RA, Sanders WL, Stroup WW. A unified approach to mixed linear models. Am Stat 1991; 45: 54-64.
19. Conover WJ. Practical nonparametric statistics. 3rd edn. New York: Wiley; 1999.
20. Meeker HC, Schuller-Levis G, Fusco F, Giardina-Becket MA, Sersen E, Levis WR. Sequential monitoring of leprosy patients with serum antibody levels to phenolic glycolipid-I, a synthetic analog of phenolic glycolipid-I, and mycobacterial lipoarabinomannan. Int J Lepr Other Mycobact Dis 1990; 58: 503-511. (Pubitemid 20319083)
21. Job CK, Jayakumar J, Kearney M, Gillis TP. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg 2008; 78: 518-521. (Pubitemid 351845207)